Karthik Subramanian

Extracellular vesicle-bound bacterial toxin pneumolysin triggers membrane engagement and damage beyond canonical pore formation

This study shows that pneumolysin, a bacterial toxin, can damage target cell membranes through vesicle fusion rather than pore formation.

Sorafenib, a clinically approved kinase inhibitor attenuates Streptococcus pneumoniae pathogenesis in vivo by targeting serine/threonine kinase StkP

This study shows that sorafenib, a cancer drug, targets StkP in Streptococcus pneumoniae, reducing bacterial pathogenesis and mortality in mice.